EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives

Lyudmila V Bel'skaya

Frontiers in Bioscience-Scholar · 2025

DOI: 10.31083/fbs36652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Scholar, 2025. Verfasst von Lyudmila V Bel'skaya. Beteiligte Einrichtung: Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Saliva, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The features of metabolic processes associated with low human epidermal growth factor receptor 2 (HER2) expression (HER2-low) in breast cancer have not been described to date, including characteristic features of immune system reactivity, the presence and content of tumor markers, and the amino acid profile.

Methods

The case-control study involved 660 volunteers with breast cancer. Saliva was used as a biological fluid; at the time of collection, the patients were not receiving any treatment. Concentrations of 7 cytokines, 4 tumor markers, 12 amino acids, and 11 biochemical parameters were determined in the saliva.

Results

It was found that the HER2-low group was characterized by the highest pro-inflammatory activity, but the lowest metabolic activity. Three functional groups of amino acids were identified, which showed reliable differences in the HER2-low subgroup. The cancer antigen 19-9 (CA 19-9) tumor marker in the HER2-low group showed the greatest deviations from normal values compared to patients in the HER2 (–) and HER2 (+) groups.

Conclusions

Thus, patients with HER2-low breast cancer status had their own characteristic features in the course of the disease, immune response and metabolic activity. Understanding the features of metabolic processes in the HER2-low subgroup can help identify new therapeutic targets for this group of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesSalivaBiomarkers, TumorHumansFemaleCase-Control StudiesMiddle AgedAdultAgedCytokinesAmino Acids

Stichwörter der Autor:innen

HER2-lowbreast cancerimmune responsemetabolic featuressaliva

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorCytokinesAmino AcidsERBB2 protein, human

Autor:innen und Institutionen

  • Biochemistry Research Laboratory, Omsk State Pedagogical University, 644099 Omsk, Russia.

Förderung

  • Russian Science Foundation

Zitieren

APA

Bel'skaya, L. V. (2025). HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives. Frontiers in Bioscience-Scholar. https://doi.org/10.31083/fbs36652

Vancouver

Bel'skaya LV. HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives. Frontiers in Bioscience-Scholar. 2025. doi:10.31083/fbs36652

BibTeX
@article{Belskaya2025,
  author = {Bel'skaya, Lyudmila V},
  title = {HER2-low Breast Cancer: Salivary Metabolic Features and Therapeutic Perspectives},
  journal = {Frontiers in Bioscience-Scholar},
  year = {2025},
  doi = {10.31083/fbs36652}
}
Kostenlos starten →